164 related articles for article (PubMed ID: 31753536)
1. Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation.
Pastori D; Sciacqua A; Marcucci R; Farcomeni A; Perticone F; Del Ben M; Angelico F; Baratta F; Pignatelli P; Violi F;
Mayo Clin Proc; 2020 Mar; 95(3):513-520. PubMed ID: 31753536
[TBL] [Abstract][Full Text] [Related]
2. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.
Pastori D; Lip GYH; Farcomeni A; Del Sole F; Sciacqua A; Perticone F; Marcucci R; Grifoni E; Pignatelli P; Violi F;
Int J Cardiol; 2018 Aug; 264():58-63. PubMed ID: 29776574
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.
Pastori D; Sciacqua A; Marcucci R; Del Ben M; Baratta F; Violi F; Pignatelli P;
Intern Emerg Med; 2021 Nov; 16(8):2063-2068. PubMed ID: 33713286
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
5. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort.
Pastori D; Pignatelli P; Menichelli D; Violi F; Lip GYH
Mayo Clin Proc; 2019 Jul; 94(7):1261-1267. PubMed ID: 30551910
[TBL] [Abstract][Full Text] [Related]
6. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
[TBL] [Abstract][Full Text] [Related]
7. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
Baratta F; Pastori D; Angelico F; Balla A; Paganini AM; Cocomello N; Ferro D; Violi F; Sanyal AJ; Del Ben M
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2324-2331.e4. PubMed ID: 31887443
[TBL] [Abstract][Full Text] [Related]
11. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
12. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.
Pastori D; Farcomeni A; Saliola M; Del Sole F; Pignatelli P; Violi F; Lip GYH;
Eur J Intern Med; 2018 Aug; 54():34-39. PubMed ID: 29655807
[TBL] [Abstract][Full Text] [Related]
16. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
[TBL] [Abstract][Full Text] [Related]
17. Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study.
Pastori D; Menichelli D; Lip GYH; Sciacqua A; Violi F; Pignatelli P;
Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008477. PubMed ID: 32718257
[TBL] [Abstract][Full Text] [Related]
18. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
19. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review.
Käräjämäki AJ; Hukkanen J; Ukkola O
Ann Med; 2018 Aug; 50(5):371-380. PubMed ID: 29929399
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.
Targher G; Mantovani A; Pichiri I; Rigolon R; Dauriz M; Zoppini G; Morani G; Vassanelli C; Bonora E
Clin Sci (Lond); 2013 Sep; 125(6):301-9. PubMed ID: 23596966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
